VELARU MANDATE EXHIBIT PACK — SYNTHETIC BIOLOGY / BIOSECURITY
Jurisdiction: Brazil (br)
Modality: Text / Chat
Program: Velaru Synthetic Biology / Biosecurity · Brazil (galactic_synthetic_biology_br)
Product ID: synthetic_biology:br:bundle:text
Vertical: synthetic_biology
Generated: 2026-08-22T07:44:21.829336Z
Authority: Brazil LGPD ADM Pack — Biosecurity AI Screening Pack
Deadline: Federal Select Agent Program + DURC
Velaru verify: https://velaru-erra.onrender.com/verify

EXHIBIT A — AI INVENTORY
[]

EXHIBIT B — GOVERNANCE FRAMEWORK
{
  "framework": "Velaru Mandate Registry \u2014 Synthetic Biology / Biosecurity",
  "exhibit_authority": "Brazil LGPD ADM Pack \u2014 Biosecurity AI Screening Pack",
  "regulatory_frameworks": [
    "Federal Select Agent Program",
    "NIH Guidelines",
    "DURC Policy",
    "LGPD Art 20",
    "ANPD AI resolution",
    "CVM AI guidance",
    "Marco Civil"
  ],
  "standards_alignment": [
    "POSS-2",
    "DRP-1",
    "TCB",
    "FRE 707 pre-compliance",
    "ISO 42001"
  ],
  "human_oversight": "synthesize DNA sequence",
  "third_party_verification": "https://velaru-erra.onrender.com/verify (operator-independent)",
  "data_lineage": "Hash-chained Ed25519 receipts; optional RFC3161 + external anchor",
  "mirror_trap": "Cloud lab orders sequence \u2014 lab owns biosecurity violation, screening vendor owns API uptime SLA. \u00b7 LGPD Art 20 review of automated decisions \u2014 receipt enables review request response.",
  "chain_integrity": {
    "depth": 5,
    "invariant_holds": true
  }
}

EXHIBIT D — DATA INPUTS & VALIDATION
{
  "data_validation_method": "Cryptographic receipt per AI decision; public verify without trusting deployer, vendor, or Velaru operator",
  "bias_testing_proxy": "Asymmetry score from live chain signals",
  "model_change_control": "Policy lock registry \u2014 criteria hash frozen pre-dispute",
  "logging_retention": "90-day pre-dispute window minimum; permanent verify permalinks",
  "external_validator": "Nisaba LLC / Velaru",
  "validator_independence": "Client-side Ed25519 verify; BYOK tri-receipt optional",
  "headline_stat": "Screening AI failure = criminal liability under Select Agent regulations",
  "global_leaders_addressed": [
    "CDC",
    "Ginkgo Bioworks",
    "Twist Bioscience",
    "NIH",
    "WHO",
    "ANPD",
    "Nubank",
    "BCB"
  ]
}

MIRROR TRAP (regulatory insight)
Cloud lab orders sequence — lab owns biosecurity violation, screening vendor owns API uptime SLA. · LGPD Art 20 review of automated decisions — receipt enables review request response.

NERVE CARDS — WHY GLOBAL LEADERS CARE
[
  {
    "title": "DURC policy",
    "body": "Dual use research of concern \u2014 AI screening decision must be documented for IBC review.",
    "source": "vertical"
  },
  {
    "title": "Sequence orders",
    "body": "Every synthesis order needs screening receipt \u2014 HHS 2010 framework now AI-accelerated.",
    "source": "vertical"
  },
  {
    "title": "Insurance exclusion",
    "body": "Biotech policies excluding unscreened AI sequence design.",
    "source": "vertical"
  },
  {
    "title": "[Brazil] LatAm hub",
    "body": "Brazil sets pattern for LATAM \u2014 receipt architecture scales to Mexico, Colombia.",
    "source": "jurisdiction"
  },
  {
    "title": "[Brazil] Fintech",
    "body": "Nubank, Mercado Libre AI \u2014 BCB expects credit decision explainability.",
    "source": "jurisdiction"
  },
  {
    "title": "[Text / Chat] Modality hook",
    "body": "Baseline \u2014 all frameworks apply to text decisions.",
    "source": "modality"
  }
]

BOOK SUMMARY: {
  "total_insureds": 0,
  "compliant": 0,
  "grace_period": 0,
  "non_compliant": 0,
  "expired": 0,
  "not_enrolled": 0,
  "compliant_pct": 0.0
}

TAM / EXPOSURE: Synthetic biology market $80B+ · DNA synthesis screening mandatory
INSURANCE LINES: Biotech E&O, Product liability

DISCLAIMER: External validation evidence pack — not legal advice, not filed rate approval.